Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06382649 · ClinicalTrials.gov registry record · Phase 2
Rivastigmine for Antimuscarinic Delirium
A Phase 2 study, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT06382649 is a Phase 2 study that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 42 participants.
The verdict
NCT06382649, a Phase 2 study, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine, the standard antidote for AMD, currently has very limited availability in the United States due to an interruption of production. Recent case reports and small observational studies suggest that rivastigmine might be useful in the treatment of AMD, but there is not direct prospective evidence comparing rivastigmine to physostigmine or supportive care. In order to investigate the effectiveness of rivastigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine for antimuscarinic delirium will experience more rapid resolution of agitation and delirium than those treated with placebo.
Interventions
- DRUG Placebo
- DRUG Rivastigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06382649
The ClinicalTrials.gov registry entry for NCT06382649 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06382649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06382649 about?
NCT06382649 is a clinical study titled "Rivastigmine for Antimuscarinic Delirium". Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine, the standard antidote for AMD, currently has very limited availability in the United States due to an interruption of pr...
What is the current status of trial NCT06382649?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2026-06. Estimated completion is 2028-12.
What interventions are being tested in trial NCT06382649?
The interventions under investigation include: Placebo (DRUG), Rivastigmine (DRUG).
Who is sponsoring clinical trial NCT06382649?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.